BE716437A - - Google Patents
Info
- Publication number
- BE716437A BE716437A BE716437A BE716437A BE716437A BE 716437 A BE716437 A BE 716437A BE 716437 A BE716437 A BE 716437A BE 716437 A BE716437 A BE 716437A BE 716437 A BE716437 A BE 716437A
- Authority
- BE
- Belgium
- Prior art keywords
- emi
- drug
- fraction
- subject
- treatment
- Prior art date
Links
- 150000003904 phospholipids Chemical class 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 210000004185 liver Anatomy 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 210000001557 animal structure Anatomy 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 239000000284 extract Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000021336 beef liver Nutrition 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003400 hallucinatory effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 208000008127 lead poisoning Diseases 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 208000001644 thecoma Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR113105A FR6776M (OSRAM) | 1967-07-05 | 1967-07-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE716437A true BE716437A (OSRAM) | 1968-11-04 |
Family
ID=8634474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE716437A BE716437A (OSRAM) | 1967-07-05 | 1968-06-12 |
Country Status (3)
| Country | Link |
|---|---|
| BE (1) | BE716437A (OSRAM) |
| FR (1) | FR6776M (OSRAM) |
| NL (1) | NL6809514A (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0228711A3 (en) * | 1986-01-02 | 1989-04-19 | American Cyanamid Company | Proteolipid compounds |
-
1967
- 1967-07-05 FR FR113105A patent/FR6776M/fr not_active Expired
-
1968
- 1968-06-12 BE BE716437A patent/BE716437A/fr not_active IP Right Cessation
- 1968-07-05 NL NL6809514A patent/NL6809514A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NL6809514A (OSRAM) | 1969-01-07 |
| FR6776M (OSRAM) | 1969-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2914188A1 (fr) | Nouvelle composition a base d'oxime de cholest-4-en-3-one | |
| EP0436650A1 (fr) | Phases lamellaires lipidiques hydratees ou liposomes a base d'ecdysteroides. | |
| JPH0455168B2 (OSRAM) | ||
| BE895724A (fr) | Nouvelle utilisation therapeutique de la dihydrocyclosporine d | |
| EP1102586B1 (fr) | Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique | |
| FR2492260A1 (fr) | Composition pharmaceutique pour l'administration orale contenant le facteur de coagulation viii | |
| US4677099A (en) | Medical processes employing a novel lipid fraction | |
| FR2744915A1 (fr) | Composition cosmetique a base de cellules indifferenciees de ginkgo biloba | |
| EP2286819A1 (en) | Pharmceuttical composition for treating cardio-cerebro vascular diseases and preparative method and kit thereof | |
| BE716437A (OSRAM) | ||
| JP2023145593A (ja) | アツバノリ属抽出物及びその使用 | |
| EP3242674B1 (fr) | Compositions contenant de la curcumine à biodisponibilité améliorée | |
| FR2885050A1 (fr) | Composition amincissante a base d'extraits de cacao. | |
| FR2619009A1 (fr) | Agent anti-hyperlipemique | |
| JP2753936B2 (ja) | ▲ｉ▼型及び▲ｉｉ▼型糖尿病改善剤の製造方法 | |
| FR2591890A1 (fr) | Composition a usage therapeutique comprenant des composes organo-silicies | |
| FR2467598A1 (fr) | Composition dermatologique contenant un ou plusieurs triglycerides et son application au traitement de la peau vivante | |
| EP3041486A1 (fr) | Utilisation de propolis pour lutter contre les effets secondaires des chimiotherapies | |
| FR2709964A1 (fr) | Compositions pharmaceutiques antivirales proposées dans le traitement du SIDA et de l'Herpès. | |
| TWI815349B (zh) | 山竹果殼萃取物用於製備促進糖尿病傷口癒合的藥物的用途 | |
| FR2756740A1 (fr) | Medicament contenant un adrenocorticosteroide, destine au traitement de l'hircisme | |
| JP4473968B2 (ja) | 血球流動性改善剤 | |
| FR2839887A1 (fr) | Nouvelles compositions nutraceutiques et pharmaceutiques et leurs utilisations | |
| FR2635462A1 (fr) | Preparation medicamenteuse a base d'extrait d'ortie urtica kiovensis (rogiwicz), leur utilisation pour le traitement de tumeurs, et procedes de fabrication | |
| FR2747308A1 (fr) | Association de margousier, de (-) hydroxycitrate et de ceramides et compositions les renfermant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE20 | Patent expired |
Owner name: GAILLARD JEAN-PIERRE Effective date: 19880612 |